AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05298397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EAT-PTSD adapted for youth for anxiety
Description: This is an eight session (90 minute sessions) weekly experiential group treatment. The first session includes psychoeducation, orientation to treatment, a barn tour, and ends with meeting the horses. Subsequent sessions involve increasingly complex encounters and interactions with horses accompanied by feedback and direction from the treatment. Early phase treatment exercises acquaint patients with the horse, with grooming exercises, leading with a rope or a wand, and directing the horse. The middle phase furthers patients' mastery and comfort with the horse in individual and teamwork exercises. The final session includes a graduation ceremony. All intervention sessions begin with Opening Circle and end with Closing Circle. Opening Circle incorporates a grounding exercise and is orients participants to the session to check in regarding thoughts and feelings. Closing Circle reviews lessons learned during the session, eliciting participant feedback and facilitating discussion.
Study NCT06464952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant potato starch
Description: Prebiotic
Study NCT06464952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Powdered cellulose
Description: Active comparator
Study NCT06001151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients receive cadonilimab (10mg/kg) every 3 weeks.
Study NCT06001151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients receive pemetrexed (500mg/m2) every 3 weeks.
Study NCT06001151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
Study NCT05759286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
Study NCT05759286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
Study NCT05759286 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
Study NCT04487353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor mechanism application developed with virtual reality technology (VRT-LMA)
Description: In phase I: VRT-LMA application was developed. (Female in lithotomy position, bony pelvis, flexion of the coccyx back about 2 cm and the Hodge plane were modeled as lines. The theory training to be given to the control group was prepared in accordance with the curriculum.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~III. In the second stage: the post-test and analyzes were performed after 5 weeks in both groups.
Study NCT05521711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Commercially available powders or liquids
Study NCT05462782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) Cone Coil
Description: The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
Study NCT05462782 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) Sham Coil
Description: The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
Study NCT06087471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention snack
Description: The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
Study NCT06087471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control Snack
Description: The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
Study NCT05296070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine 150 µg/Kg
Description: Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
Study NCT05296070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine 75µg/Kg
Description: Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
Study NCT05984173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E application
Description: patients received vitamin E inside the socket after extraction
Study NCT04735796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：LM-102
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
Study NCT05050500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg/Tab
Description: patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
Study NCT05050500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
Study NCT04992624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Study NCT04992624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Study NCT04992624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Description: Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Study NCT04990271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept ophthalmic injection
Description: Monthly injection of Conbercept from 0\~5 months
Study NCT05987592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Education and WELLness with Migraine Group A
Description: Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
Study NCT05987592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Education and WELLness with Migraine Group B
Description: Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
Study NCT05132855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
Study NCT05132855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
Study NCT05132855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
Study NCT04696783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium Enteric-coated Tablets
Description: Nexium taken once every 2 days plus lifestyle adjustment
Study NCT04696783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle adjustment
Description: Lifestyle adjustment
Study NCT04696783 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle adjustment
Description: Lifestyle adjustment
Study NCT05891106 — intervention group
Intervention type: DEVICE
Intervention: Lotrafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses
Study NCT06330675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Short-term bed-rest and immobilization
Study NCT06330675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Bed-rest and immobility until the day-after procedure
Study NCT06408350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Me, Alexis!
Description: Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression
Study NCT05276960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol Pill
Description: Dose increments according to serum levels determined every 2 months
Study NCT05276960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Pill
Description: Dose increments according to serum levels determined every 2 months
Study NCT06006637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
Study NCT06006637 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
Study NCT05119686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 1
Description: Solid Oral Capsule
Study NCT05119686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 2
Description: Solid Oral Capsule
Study NCT05119686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Solid Oral Capsule Placebo
Study NCT06379529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NuvoAir clinical service
Description: Patients with COPD receiving usual care plus NuvoAir clinical services.
Study NCT04418414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene therapy
Description: CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
Study NCT04418414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological
Description: G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
Study NCT05859711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thyme honey mouth rinse
Description: oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
Study NCT05859711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline mouth rinse
Description: saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
Study NCT05580211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem modulation device (stimulation Randomized)
Description: Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
Study NCT05580211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem modulation device (stimulation-Open Label)
Description: Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
Study NCT05968885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradetrusor Botox® (onabotulinumtoxinA) injection
Description: The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
Study NCT05968885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combine Mirabegron and Solifenacin.
Description: Combination pharmacotherapy
Study NCT04665297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Guide for Monitoring Child Development
Description: Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
Study NCT06712121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine plus venetoclax
Description: decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days
Study NCT06731452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
Description: Online SMART is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~Stress Solutions extends the SMART principles to relevant domains of stress and resilience.
Study NCT06263439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Throat/buccal swab sample
Description: The study involves the genome detection of enteroviruses in throat or mouth swabs taken from children with a diagnosis of HFMD or herpangina. If positive, the precise type of enterovirus responsible will be identified by sequencing a viral genomic region.
Study NCT05553093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide ih qw
Study NCT05553093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: 6 IU ih qd
Study NCT05395923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture
Description: The pressure application will be applied before the incision on the palate.
Study NCT05395923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Suture CTG -Control
Description: A graft will be taken from the palate before the procedure is applied.
Study NCT06028165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting based on conventional coronary angiography
Description: Revascularized coronary arteries are decided based on conventional coronary angiography (quantitative coronary angiography)
Study NCT06028165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.
Description: Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
Study NCT04767334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-Gravity Treadmill
Description: Each participant will started with a 5 - 10 minute warm-up on a standard cycle ergometer, manual and therapeutic therapy for upper extremity, and gait training using LBPP. Manual and therapeutic therapy will consist of passive and active ROM, joint mobilization, passive and active stretch, manual resistance exercise, and activities of daily life (ADL). All participants will walk in Alter G one session a day (for 40 min), three days a week, for six weeks. On session one, the Alter G pressure chamber will be set to unload 50% of patient's body weight. On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented.
Study NCT04839055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A Combined With Abiraterone
Description: Abiraterone 4 pieces per day. Coenzyme A 200U
Study NCT04839055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone
Study NCT04786418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.
Study NCT04786418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Description: The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.
Study NCT05549349 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Gallbladder removal
Study NCT05401383 — intervention group
Intervention type: DEVICE
Intervention: Lumevis (IIa class)
Description: intake of Lumevis 30 minutes before EGDS
Study NCT05597423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
Study NCT05597423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
Study NCT05578430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg by intravenous infusions every 3 weeks
Study NCT05578430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed per institutional standard of care.
Study NCT05578430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed per institutional standard of care.
Study NCT05260099 — intervention group
Intervention type: DEVICE
Intervention: LPS Adsorber
Description: LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
Study NCT01298882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein